Bausch + Lomb acquires JnJ eye, contact lens drops brand Blink for USD 106.5 million
Advertisement
Bausch + Lomb acquired Johnson & Johnson's eye and contact lens drops brand Blink for $106.5 million, marking its second deal in two weeks to bolster the contact lens maker's portfolio of eye care products.
J&J's Blink portfolio of over-the-counter drugs include several eye drops and contact lens rewetting drops that are used to relieve dry eye symptoms, Bausch + Lomb said on Thursday.
Last week, Bausch + Lomb struck a $1.75 billion deal with Swiss drugmaker Novartisto buy several eye-care products, including anti-inflammation eye drop Xiidra.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.